SCHEMBL5846148

SCHEMBL5846148

N#CCCSN1C(=O)CCC1=O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM5 P08912 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30
ALDH1A1 P00352 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5846372 0.82 KMT2A (0.30) KMT2A
SCHEMBL3468977 0.73 POLB (0.31) POLB
SCHEMBL12485891 0.73 BRD4 (0.31) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL14408262 0.71 CHRM2 (0.46) KMT2ACHRM2CHRM4CHRM5CHRM1
SCHEMBL20503180 0.70 FAAH (0.36) KMT2ACHRM2CHRM4CHRM5CHRM1
SCHEMBL5081884 0.69 L3MBTL1 (0.46) KMT2ACHRM2CHRM4CHRM5CHRM1
SCHEMBL5810929 0.68 ALDH1A1 (0.42) KMT2ACHRM2CHRM4CHRM5CHRM1
SCHEMBL919534 0.68 DRD3 (0.45) KMT2ACYP1A2CYP2C19CYP2D6ALDH1A1
SCHEMBL5847509 0.68 FAAH (0.39) KMT2ACYP1A2CYP2C19CYP2C9POLB
SCHEMBL3988129 0.68 CHRM2 (0.47) KMT2ACHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US claimed
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2023-06-22 US claimed
US-5708161-A Nucleoside phosphorothioate derivatives, synthesis and use thereof KING'S COLLEGE LONDON (GB) 1998-01-13 US claimed
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US disclosed
CN-113631564-B Method for producing oligonucleotide having phosphorothioate site 味之素株式会社 2025-02-25 CN disclosed
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2023-06-22 US disclosed
US-11548910-B2 Oligonucleotide production method NISSAN CHEMICAL CORPORATION (JP) 2023-01-10 US disclosed
EP-3950698-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE AJINOMOTO CO., INC. (JP) 2022-02-09 EP disclosed
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE AJINOMOTO CO., INC. (JP) 2022-01-13 US disclosed
US-20190169223-A1 OLIGONUCLEOTIDE PRODUCTION METHOD NISSAN CHEMICAL CORPORATION (JP) 2019-06-06 US disclosed
EP-3378869-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Nissan Chemical Corporation (JP) 2018-09-26 EP disclosed
US-7022833-B2 Process for the preparation of phosphorothioate triesters AVECIA LIMITED (GB) 2006-04-04 US disclosed
EP-1272501-B1 PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AVECIA LTD (GB) 2004-05-06 EP disclosed
US-20030099981-A1 Process for the preparation of phosphorothioate triesters NITTO DENKO AVECIA, INC. 2003-05-29 US disclosed
EP-1272501-A1 PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS Avecia Limited (GB) 2003-01-08 EP disclosed
WO-2001064702-A1 PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AVECIA LIMITED (GB) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE RNGTT, NUDT1, ADAR KMT2A 2596/4885CHRM2 4872/4885CHRM4 4836/4885
US-11548910-B2 Oligonucleotide production method RNGTT, OSGEP, PHAX KMT2A 2395/4885CHRM2 4882/4885CHRM4 4736/4885
US-20190169223-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, OSGEP, PHAX KMT2A 2395/4885CHRM2 4882/4885CHRM4 4736/4885
US-20030099981-A1 Process for the preparation of phosphorothioate triesters OSGEP, NUDT1, PNKP KMT2A 2625/4885CHRM2 4766/4885CHRM4 4194/4885
US-12492220-B2 Method for the preparation of oligonucleotides POLN, POLRMT, POLI KMT2A 3340/4885CHRM2 4878/4885CHRM4 4408/4885
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES POLN, POLRMT, POLI KMT2A 3340/4885CHRM2 4878/4885CHRM4 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.